October 31, 2017
USADA announced today that a three-member panel of the American Arbitration Association (AAA) has rendered its decision in the case of weightlifting athlete Amy Hay, of Portland, Ore., and has determined that Hay should receive a two-year sanction after testing positive for a prohibited substance.
Hay, 26, tested positive for ostarine as the result of an in-competition urine sample she provided on March 18, 2017, at the American Open Series 1. Ostarine is a non-Specified Substance in the class of Anabolic Agents and prohibited at all times under the USADA Protocol for Olympic and Paralympic Movement Testing, the United States Olympic Committee National Anti-Doping Policies, and the International Weightlifting Federation Anti-Doping Rules, all of which have adopted the World Anti-Doping Code and the World Anti-Doping Agency Prohibited List.
Ostarine, also known as MK-2866 and Enobosarm, is a non-FDA approved selective androgen receptor modulator (SARM) that is illegally sold in the United States and worldwide as a performance-enhancing substance. Ostarine is not currently available as a prescription medication in any country, and its unauthorized use may carry serious side effects. Nonetheless, ostarine has been found as a declared and undeclared ingredient in many dietary supplements sold in the United States, which has prompted the U.S. Food and Drug Administration (FDA) to issue warning letters to specific dietary supplement manufacturers stating that ostarine is an unapproved new drug and that selling the drug is in violation of the Federal Food, Drug, and Cosmetic Act. More information about the risks of ostarine can be found through a USADA athlete advisory.
Hay’s two-year period of ineligibility began on April 11, 2017, the date she accepted a provisional suspension. In addition, Hay has been disqualified from all competitive results obtained on and subsequent to March 18, 2017, the date her positive sample was collected, including forfeiture of any medals, points and prizes. As such, Hay’s results at the American Open Series 1 have been disqualified, including her first place result on March 18, 2017.
The AAA award, as well as other arbitral decisions, can be found here.
In an effort to aid athletes, as well as all support team members such as parents and coaches, in understanding the rules applicable to them, USADA provides comprehensive instruction on its website on the testing process and prohibited substances, how to obtain permission to use a necessary medication, and the risks and dangers of taking supplements as well as performance-enhancing and recreational drugs. In addition, USADA manages a drug reference hotline, Global Drug Reference Online (www.GlobalDRO.com), conducts educational sessions with National Governing Bodies and their athletes, and proactively distributes a multitude of educational materials, such as the Prohibited List, easy-reference wallet cards, periodic newsletters, and protocol and policy reference documentation.
USADA is responsible for the testing and results management process for athletes in the U.S. Olympic and Paralympic Movement, and is equally dedicated to preserving the integrity of sport through research initiatives and educational programs.